Metraipolis › archive › dc_b92d88d5efff

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer — Europe PMC PMID:41826432

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41826432
DOI
10.1038/s41698-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-04T10:42:29.739Z
SHA-256 of the archived text
9773aaa88380bc091e11eef97bb85011a89b3833b9ab13b26e13eb0193d71739
Stable URL of this page
https://metraipolis.com/documento/dc_b92d88d5efff

How to cite

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer — Europe PMC PMID:41826432 — Europe PMC (en), https://europepmc.org/article/MED/41826432 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b92d88d5efff (Metraipolis archive dc_b92d88d5efff, sha256 9773aaa88380bc091e11eef97bb85011a89b3833b9ab13b26e13eb0193d71739)
BibTeX
@misc{dcb92d88d5efff,
  title = {Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer — Europe PMC PMID:41826432},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41826432},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b92d88d5efff; sha256 9773aaa88380bc091e11eef97bb85011a89b3833b9ab13b26e13eb0193d71739},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41826432. Agents can read the archived copy with the MCP tool read_document.